Spinal Muscular atrophy therapeutics development in SMA: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 11: Line 11:


''Histone deacetylase inhibitors''' (Lunke 2009, Sumner 2006, Chang 2001).
''Histone deacetylase inhibitors''' (Lunke 2009, Sumner 2006, Chang 2001).
*'''Phenylbutyrate'''  
*'''Phenylbutyrate'''  
*'''Valproic acid''' - already widely used in treatment of [[Epilepsy]]
*'''Valproic acid''' - already widely used in treatment of [[Epilepsy]]
*'''LBH589 (hydroxamic acid)''', already widely used in [[cancer]] clinical trials  
*'''LBH589 (hydroxamic acid)''', already widely used in [[cancer]] clinical trials  




Drugs that are not histone deacetylase inhibitors, but that also affect SMN2 gene expression levels or promote inclusion of exon 7 are-
Drugs that are not histone deacetylase inhibitors, but that also affect SMN2 gene expression levels or promote inclusion of exon 7 are-


*'''Albuterol''', a [[beta-adrenergic agonist]] already widely used in treatment of [[Asthma]].
*'''Albuterol''', a [[beta-adrenergic agonist]] already widely used in treatment of [[Asthma]].
*'''Indoprofen''' is a [[Non-steroidal anti-inflammatory]] drug.
*'''Indoprofen''' is a [[Non-steroidal anti-inflammatory]] drug.


Line 25: Line 30:


*'''Aminoglycosides''' appear to promote read-through of the [[stop codon]] and thereby stabilize the [[SMN]] protein (Wolstencraft 2005).   
*'''Aminoglycosides''' appear to promote read-through of the [[stop codon]] and thereby stabilize the [[SMN]] protein (Wolstencraft 2005).   
*'''[[Riluzole]] and [[Gabapentin]]''' (Haddad 2003).
*'''[[Riluzole]] and [[Gabapentin]]''' (Haddad 2003).
*'''[[NMDA receptor activation]]''' (Biondi, 2010).  
*'''[[NMDA receptor activation]]''' (Biondi, 2010).  
*'''[[Antisense oligonucleotides]]''' ([[ASO]]) have been shown to prevent skipping of [[exon]] 7, that in turn enhances production of full-length SMN [[mRNA]] in [[fibroblasts]] from patients (Singh et al. 2009
*'''[[Antisense oligonucleotides]]''' ([[ASO]]) have been shown to prevent skipping of [[exon]] 7, that in turn enhances production of full-length SMN [[mRNA]] in [[fibroblasts]] from patients (Singh et al. 2009
*'''[[Stem cells therapy]]''' - [[Pluripotent]] stem cells with the capacity to differentiate into motor neurons could serve as an important model system (Ebert 2009).
*'''[[Stem cells therapy]]''' - [[Pluripotent]] stem cells with the capacity to differentiate into motor neurons could serve as an important model system (Ebert 2009).
*'''[[Gene therapy]]''' (Foust 2010)
*'''[[Gene therapy]]''' (Foust 2010)

Revision as of 18:30, 24 June 2011

Spinal Muscular Atrophy Microchapters

Home

Patient Info

Overview

Epidemiology and Demographics

Risk Factors

Screening

Other forms

Molecular Biology

Genetics

Types

Diagnosis

Diagnosis

Full Differential Diagnosis

Symptom

Physical Examination

Electrolyte & Biomarker Studies

Electrocardiogram

Chest X Ray

MRI and CT

Echocardiography or Ultrasound

Other Imaging Findings

Pathology

Other Diagnostic Studies

Treatment

Outcome measures

Therapeutics development

Indications For Surgery

Research

Pre-Operative Assessment

Post-Operative Assessment

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Spinal Muscular atrophy therapeutics development in SMA Resources

Most recent articles on Spinal Muscular atrophy therapeutics development in SMA

Most cited articles on Spinal Muscular atrophy therapeutics development in SMA

Review articles on Spinal Muscular atrophy therapeutics development in SMA

Review articles on Spinal Muscular atrophy therapeutics development in SMA

CME Programs on Spinal Muscular atrophy therapeutics development in SMA

Powerpoint slides on Spinal Muscular atrophy therapeutics development in SMA

Images of Spinal Muscular atrophy therapeutics development in SMA

Ongoing Trials on Spinal Muscular atrophy therapeutics development in SMA at Clinical Trials.gov

US National Guidelines Clearinghouse on Spinal Muscular atrophy therapeutics development in SMA

NICE Guidance on Spinal Muscular atrophy therapeutics development in SMA

FDA on Spinal Muscular atrophy therapeutics development in SMA

CDC on Spinal Muscular atrophy therapeutics development in SMA

Spinal Muscular atrophy therapeutics development in SMA in the news

Blogs on Spinal Muscular atrophy therapeutics development in SMA

Directions to Hospitals Treating Spinal Muscular atrophy therapeutics development in SMA

Risk calculators and risk factors for Spinal Muscular atrophy therapeutics development in SMA

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

SMA disease severity has been found to be inversely related to the number of SMN2 gene and the amount of SMN protein present. Efforts are being directed to develop agents that can increase the amount of SMN2 gene and the SMN proteins. Also, other approaches like stem cell therapy, gene therapy are active areas of research. There is no standard treatment of SMA till date. However, the recent developments in molecular genetics have helped in understanding the pathogenesis of the disease and raises hope for a future treatment. Below are the drugs that have been actively studied in animal models and various clinical trials.

Drugs that act by increasing SMN protein, number of SMN2 gene, number of nuclear gems


Histone deacetylase inhibitors' (Lunke 2009, Sumner 2006, Chang 2001).

  • Phenylbutyrate
  • Valproic acid - already widely used in treatment of Epilepsy
  • LBH589 (hydroxamic acid), already widely used in cancer clinical trials


Drugs that are not histone deacetylase inhibitors, but that also affect SMN2 gene expression levels or promote inclusion of exon 7 are-



Other approaches-

  • Aminoglycosides appear to promote read-through of the stop codon and thereby stabilize the SMN protein (Wolstencraft 2005).
  • Stem cells therapy - Pluripotent stem cells with the capacity to differentiate into motor neurons could serve as an important model system (Ebert 2009).